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In search of a non-invasive alternative detection of early-stage cardiac allograft vasculopathy (CAV), in the 
preliminary study we tested the hypothesis that interstitial fibrosis quantified with cardiac magnetic 
resonance (CMR) can serve as a biomarker for the detection of CAV.  
Methods 
Late-stage CAV was detected with routine X-ray coronary angiography (XRCA), while a coronary intima-
media thickness ratio (IMTR)>1 on optical coherence tomography (OCT) was used to detect early-stage 
CAV. Interstitial fibrosis was quantified in the endomyocardial biopsy (EMB) and indirectly with CMR as 
the T1 relaxation time and extracellular volume (ECV). CMR was performed within 48h of a single invasive 
procedure with XRCA, OCT, and EMB procurement in stable HTx recipients (n=27; age 54±13y, 5.4±3.7y 
posttransplant).  
Results 
XRCA-CAV and IMTR>1 were present in 15% and 75% of study patients, respectively. The T1 relaxation 
times and ECV were increased in patients with XRCA-CAV (p=0.03 each), while IMTR and EMB 
interstitial fibrosis were not significantly different (both P>0.05). ECV (ρ=0.46, P=0.02) and IMTR (ρ=0.58; 
P=0.01) correlated with the histological quantity of interstitial fibrosis, while the T1 relaxation time (P=0.06) 
did not.  
Conclusions 
The correlation of the IMTR with the EMB interstitial fibrosis tentatively validates the hypothesis that 
interstitial fibrosis may serve as an early indicator of CAV. Moreover, the significant association of CMR-
based ECV with the magnitude of interstitial fibrosis in the biopsy suggests ECV as a potential biomarker 
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for interstitial fibrosis due to early-stage CAV. The measurement of ECV may therefore have a role for non-
invasive detection and follow-up of early-stage CAV. 
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Heart transplantation (HTx) remains the definitive treatment for eligible patients with end-stage heart 
failure. Survival after heart transplantation has substantially increased during the last two decades due to the 
significant decrease of all-cause mortality primarily within the first 12 months. However, the mid- and long-
term survival after HTx has not substantially improved [1].  
Cardiac allograft vasculopathy (CAV) is still among the leading causes of mid-term and late post-transplant 
mortality [1], despite significant effort to increase comprehension of the complex interplay of various 
contributing factors [2], CAV is characterized by diffuse intimal hyperplasia that affects the coronary 
circulation in a longitudinal and concentric arteriovascular pattern [3]. Invasive X-ray based coronary 
angiography (XRCA) remains the routine for CAV detection but is primarily sensitive to luminal pathology, 
which is a characteristic of late-stage CAV [4]. High-resolution optical coherence tomography (OCT) 
enables the visualization of the inner layers of the coronary artery vessel wall and has recently been used 
for the detection of intimal hyperplasia, which has been shown to occur already early after HTx when 
luminopathologic changes characteristics of CAV are not present [5,6]. The spatial resolution of OCT (10-
20 µm) is ten-fold higher than that of intravascular ultrasound (IVUS, 100-150 µm), and while the 
penetration depth is lower, it thus allows for an accurate high-resolution visualisation of the tunica intima 
and media [6]. However, OCT-based imaging of the coronary vascular wall is not extensively applied for 
technical and financial reasons as well as its need for extra contrast medium, which precludes the standard 
application of this technique in HTx recipients with more advanced kidney disease [7]. All the same, 
detection of early-stage CAV remains essential since immunosuppression with mTOR (mammalian target 
of rapamycin) inhibition has the potential to slow or even inhibit CAV progression if introduced before the 
advent of irreversible damage of the coronary artery vessel wall [8].  
Histological studies suggest that CAV starts with endothelial injury [2,9], followed by capillary rarefication 
[10,11] and impaired adaptation of the myocardial blood flow to exercise-induced myocardial oxygen 
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demand (Figure 1). Subsequent diffuse myocardial hypoxia has been shown to result in an increase of the 
magnitude of interstitial fibrosis [12,13], which led us to hypothesize that myocardial interstitial fibrosis 
could be not only a biomarker for late-stage CAV, but for early-stage CAV as well. Myocardial fibrosis can 
be quantified by gold-standard automated colour segmentation of histological images obtained from 
endomyocardial biopsy (EMB) [14], and has been shown to strongly correlate with the myocardial 
longitudinal (T1) relaxation time and extracellular volume (ECV) that can be non-invasively mapped with 
cardiovascular magnetic resonance (CMR) [15,16]. These two quantitative CMR measures differ in that 
native (i.e. pre-contrast-agent) T1 mapping is sensitive to changes in many components of the myocardium, 
which for example also includes changes caused by oedema, which makes it less specific in many cases 
[16]. The ECV, however, exploits the extracellular nature of contrast agents and is a measure of the non-
cellular space that is mostly occupied by the extracellular matrix. Since the extracellular matrix is largely 
composed of collagen fibres, ECV correlates with the myocardial collagen volume fraction as already shown 
across different entities of human cardiac pathology [17,18]. However, it should also be noted that ECV 
cannot be measured in all HTx recipients because of the potentially serious secondary effects of gadolinium-
based contrast agents in those with more advanced renal insufficiency.  
Therefore, as a proof of the concept that the non-invasive measurement of interstitial fibrosis could serve as 
an alternative to invasive screening of CAV, the aim of this study was to test the hypothesis that the amount 
of myocardial interstitial fibrosis as quantified with CMR can serve as a biomarker for the detection of CAV.  
Methods 
Study population 
The local ethics committee approved the study; all participants provided written informed consent (protocol 
CER Vaud 2016-00635). All experiments were performed in accordance with relevant guidelines and 
regulations. Stable cardiac allograft transplant patients (n=27, mean age: 54±13 years) (Table 1) at least 6 
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months after surgery were included (average post-transplant time: 5.4±3.7 years, range 1-17 years) in order 
to investigate CAV from early onset to more advanced stages. HTx recipients without complete explantation 
of cardiovascular implantable electronic devices or with residual leads were excluded. HTx recipients with 
an estimated glomerular filtration rate (GFR) <30 ml/min/1.73 m2, claustrophobia, or acute cellular rejection 
in the preceding EMB were not included. Donor hearts were always free of segmental dyskinesia on 
echocardiography. Donor coronary angiograms obtained in ≥50 years-old donors were free of significant 
luminal pathology. Induction therapy in the immediate postoperative phase was started with thymoglobulin 
in 37% of patients and with basiliximab in 63% of study participants. Immunosuppressive maintenance 
therapy was adapted to the individual patient within the limits of the site-specific protocol [4]. XRCA, OCT 
and EMB procurement were performed within one single per-protocol intervention; CMR was always 
performed within 48 hours of this intervention. All study participants were treated with valganciclovir for 
at least 3 months in the immediate phase after HTx; cytomegalovirus (CMV)-negative HTx recipients with 
CMV-positive donor cardiac allograft received 6 months of treatment.  
Coronary X-ray angiography 
Routine XRCA was performed on standard equipment (Allura, Philips, Amsterdam, The Netherlands) using 
a 6F guiding catheter via right radial or right femoral artery access. The coronary arteries were imaged after 
administration of intracoronary nitro-glycerine (50 μg) into the right coronary artery (RCA) or left main 
coronary artery. At least two orthogonal projections of each coronary artery were acquired. Two 
interventional cardiologists (J.F.I. and S.D.) independently graded the severity of CAV (hereafter called 
XRCA-CAV) with a scale ranging from 0 (=not significant) to 3 (=severe) on the basis of luminographic 
pathology [4], which remains the clinical reference standard even though it can only be used to detect late-
stage CAV. In cases of differences in CAV grading, a consensus was sought after joint reinvestigation. 
Optical coherence tomography 
OCT was performed using a Dragonfly Optis Imaging catheter system (St. Jude Medical, St. Paul, 
Minnesota, USA) in 24/27 patients. The catheter was placed either into the middle segment of the RCA or 
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the left anterior descending artery. After intracoronary administration of 50 μg nitro-glycerine, OCT 
imaging was performed by automated pullback over 54 mm at a speed of 20 mm/s, a radial resolution of 20 
µm, and a frame density of 10 frames/mm. Quantitative cross-sectional OCT analysis was performed off-
line using a dedicated OCT workstation (Ilumien Optis Offline Review Workstation, St. Jude Medical, St. 
Paul, Minnesota, USA). All cross-sectional images were initially reviewed for quality. Frames were 
excluded when a side branch was present in >45° of the cross section, in the case of inadequate image quality 
due to residual blood, artefact or reverberation, or if segments contained atherosclerotic plaque. The layers 
were analysed according to OCT consensus standard definitions [19]. The lumen, intima and media layers 
were traced manually every 52 frames starting at 35 mm from the vessel ostium. Vessel layer assessment 
included measurements of lumen area, intima layer area and media layer area obtained by averaging the 
lumen-intima, intima-media and media-adventitia interface contours for the entire analysed segment. The 
intima-media thickness ratio (IMTR) was calculated by dividing the average area of each layer over the 35 
mm of the analysed vessel. An IMTR >1 was considered pathologic [6], and will be referred to as OCT-
CAV. 
Histology of the endomyocardial biopsy 
The quantification of interstitial fibrosis in the individual study patient was based on Van Gieson’s staining 
[14] of 3 separate EMB specimens. Slides were scanned with a NanoZoomer S60 (Hamamatsu Photonics, 
Hamamatsu, Japan) with a spatial resolution of 2.2 pixels/µm (i.e. 454 nm). The percentage of fibrosis was 
then automatically quantified by colour segmentation with SlidePath (Leica Biosystems, Wetzlar, 
Germany). Samples that included scar tissues from previous biopsy sites were excluded to avoid 
confounding the quantification of pathological interstitial fibrosis with scar fibrosis. 
Cardiovascular magnetic resonance 
Myocardial segmented k-space T1 mapping (breath-held MOLLI [20], slice thickness 8mm, RF excitation 
angle 35°, echo time 1.12ms, repetition time 3.2ms, matrix size 256×144 interpolated to 256×218, 
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interpolated pixel size 1.9×1.9mm2, parallel imaging (GRAPPA) factor 2, pixel bandwidth 1085 Hz/pixel) 
was used to assess 2 short-axis slices (1 midventricular and 1 basal) at a magnetic field strength of 3T 
(Magnetom Prisma, Siemens Healthcare, Erlangen, Germany) with a 32-element RF coil for signal 
reception. Maps were acquired before and 19-27 min after gadolinium contrast agent injection (Gadovist, 
0.1 ml/kg) in the 48h following XRCA. A 3(3)5 MOLLI scheme was used pre-contrast, while a 4(1)3(1)2 
scheme was used post-contrast. Pre- and post- contrast T1 maps were generated in Matlab (The Mathworks, 
Natick, Massachusetts, USA), after which the entire myocardium was segmented, and both the native T1 
and ECV of the entire segmented myocardium of both slices were computed. Cine functional imaging and 
late gadolinium enhancement were not performed due to time constraints. Haematocrit (Hct) was assessed 
as part of the routine blood workup on the same day as the EMB. 
Statistical analyses 
An unpaired two-tailed Student’s t-test was used to establish whether the presence of XRCA-CAV is linked 
to differences in IMTR, EMB-based quantification of interstitial fibrosis, T1 relaxation time, or ECV. A 
Pearson correlation was calculated to ascertain whether there is a link between the IMTR or fibrosis on the 
one hand, and the T1 or ECV values on the other hand. P<0.05 was considered significant, and Bonferroni 
correction was used to compensate for multiple comparisons. Receiver-operator curves (ROC) were 
generated for all techniques to detect XRCA-CAV>0 and IMTR>1, and the area under the curve (AUC) 
was calculated. All calculations were performed in Matlab and Prism (Graphpad, La Jolla, California, USA). 
Results 
No medical complications related to the procedures occurred in any of the patients. Clinical characteristics 
of the study participants are summarized in Table 1. First, the measurements of vascular characteristics 
(XRCA and OCT) and myocardial characteristics (histology and CMR) are reported by themselves. This is 
followed by the observed differences between grouped XRCA-CAV-positive and -negative patients. 
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Finally, the correlations between the EMB fibrosis and the other modalities as well as the correlations 
between the IMTR and the other modalities are presented. 
Vascular characteristics 
XRCA was successfully completed in all patients (Table 2, Supplementary Table 1). Four study participants 
presented XRCA-CAV (15%) with an average grade of 1.5±1.0 (Figure 2A,B). Non-significant focal 
atherosclerotic lesions were visualized on XRCA in 11/27 patients (41%; 3 single-vessel, 3 two-vessels, 5 
three-vessel disease). 
High-quality OCT images were obtained in 20/27 patients (74%, Figure 2C-F); insufficient image quality 
was caused by incomplete blood washout during data acquisition (n=4 patients), diffuse atherosclerosis (n=2 
patients), and technical complications (n=1). Most OCT data were acquired in the right coronary artery 
(n=18 patients); 2 datasets were obtained in the left anterior descending coronary artery because of 
anticipated incomplete blood washout in the dominant RCA. Pathologic IMTR was present in 15/20 patients 
(75%); the average IMTR was 1.56±0.63 (range 0.68-2.71). All patients with XRCA-CAV had IMTR>1; 
their average IMTR was 2.01±0.81. 
Myocardial characteristics 
Histological analysis of the EMB was performed in 25/27 patients (93%, Figure 3A,B, Table 2); 1 EMB 
was scar tissue only, and 1 procurement was not performed due to technical difficulties. Colour 
segmentation demonstrated a wide range of interstitial fibrosis (average 29±20%, range 5-78%).  
CMR resulted in high-quality pre- and post-contrast T1 maps in all patients (Figure 3C-F). The myocardium 
appeared homogeneous on all native and post-contrast maps, i.e. no focal or patchy T1 elevation was 
observed, which indicates the absence of magnetic field inhomogeneities, artefacts, and focal disease. The 
average myocardial T1 relaxation time was 1256±49 ms (range 1169-1382 ms) pre-gadolinium, while it 
amounted to 623±61 ms (range 544-852 ms) post-gadolinium. This resulted in an average myocardial ECV 
of 31.9±4.8% (range 26.5-49.8%). 
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Associations with XRCA-based detection of CAV 
Interstitial fibrosis quantified by colour segmentation of the EMB as well as IMTR were not significantly 
different between groups with or without XRCA-CAV (P=0.11 and P=0.25, respectively), although both 
were numerically higher in patients with XRCA-CAV (Figure 4A,B). By contrast, T1 values and ECV were 
both significantly higher in recipients with XRCA-CAV (P=0.03 both, Figure 4C,D). The ROC analysis for 
the detection of XRCA-CAV>0 showed a similar moderate AUC for all techniques: 0.74 (P=0.14) for 
IMTR, 0.71 (P=0.14) for histology, 0.73 (P=0.15) for the T1 relaxation time, and 0.75 (P=0.12) for the ECV. 
Correlations with interstitial fibrosis and intimal thickening 
The magnitude of histological interstitial fibrosis correlated by trend with the native T1 relaxation time 
(ρ=0.37; P=0.06) and significantly with ECV (ρ=0.46; P=0.02, Figure 5A,B) in accordance with previous 
studies reporting on other human cardiac pathologies [21,22]. IMTR was significantly correlated with the 
amount of histological interstitial fibrosis (ρ=0.58; P=0.01, Figure 6A), but was associated with neither the 
T1 relaxation time nor with the ECV (Figure 6B,C). The ROC analysis for the detection of OCT-CAV (i.e. 
IMTR>1) agreed with these observations, and resulted in low AUC values for the XRCA-CAV score 
(AUC=0.67, P=0.26), T1 relaxation time (AUC=0.55, P=0.63), and ECV (AUC=0.68, P=0.27), while the 
histology had a moderate AUC of 0.79 (P=0.07).  
Discussion 
In this study we used five different measurements of pathologic features associated with cardiac allograft 
vasculopathy (CAV) in order to assess whether interstitial fibrosis as quantified with CMR could serve as a 
surrogate marker for CAV. XRCA was used for characterization of late-stage CAV with luminal pathology, 
while OCT was applied for detection of intramural disease that is representative of early-stage CAV. The 
amount of interstitial fibrosis, already known as a primary non-vascular sequela of CAV in its later stages 
[23,24], was quantified both histologically in the EMB and indirectly by CMR-based mapping of the T1 
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relaxation time and ECV - both recently established techniques in clinical routine [16]. This study confirms 
1) the hypothesis that the amount of interstitial fibrosis in the biopsy of the cardiac allograft increases with 
the intima-media thickness ratio (IMTR), which is the most sensitive marker for early-stage CAV [25], and 
2) that the measurement of ECV correlates with the magnitude of interstitial fibrosis in the biopsy.  
CAV remains a major limitation for long-term success after cardiac transplantation. However, recent 
evidence suggests that conversion of immunosuppression to the mammalian target of rapamycin (mTOR) 
attenuates disease progression in particular in cases with early-stage CAV [23,24]. Recently, OCT has been 
used to show that the intima area increases by 20% within the first year after HTx while there was an overall 
2% decrease of the coronary lumen [25]. These results indicate that intimal pathology already occurs early 
after HTx, and that OCT is highly suited for diagnosis and follow-up of early-stage CAV. OCT measures 
in the present study showed that a pathological IMTR of >1 was present in 75% of all study participants, 
while luminal (late-stage) pathology associated with CAV was present in only 15% of all study participants. 
The high prevalence of pathologic IMTR can explain why IMTR was not significantly different between 
HTx recipients with or without XRCA-CAV suggesting that intimal hyperplasia preceded the advent of 
intraluminal pathology in the majority of study participants [4]. In fact, every study participant with XRCA-
CAV had a pathologic IMTR in the present study. These observations together with the widely different 
prevalence of intraluminal CAV pathology and pathologic IMTR provide further support to the idea that 
intima proliferation precedes luminal pathology [6,23,25] and that OCT is the most suited diagnostic means 
for detection of early-stage CAV. 
However, OCT is an invasive, expensive, and technically demanding exam, which limits its broad 
application. We therefore investigated the interrelation of interstitial fibrosis with early-stage CAV. IMTR 
correlated strongly with the magnitude of interstitial fibrosis in the endomyocardial biopsy in the present 
study, indicating that early-stage CAV is already associated with an increase of cardiac allograft interstitial 
fibrosis. In fact, in another study it was found that the magnitude of interstitial fibrosis increased with time 
after heart transplantation, and that this progression was accompanied with an augmented expression of 
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biomarkers of hypoxia, the oxygen sensor prolyl hydroxylase 3, and the vascular endothelial growth factor 
[13]. The increase of myocardial fibrosis is thus most likely not exclusively limited to advanced 
vasculopathy as suggested earlier [26], but might occur already with early-stage CAV. This makes the 
detection of early-stage CAV even more essential, because the increase of myocardial fibrosis contributes 
to diastolic and systolic dysfunction of the cardiac allograft [27], which reduce the benefit of heart 
transplantation. 
Native T1 mapping and ECV measurement introduced novel quantitative metrics for the assessment of 
alteration of tissue composition after heart transplantation. Post-contrast T1 mapping, which can be seen as 
a quantitative version of the widely used late gadolinium enhancement (LGE) imaging, did not reveal focal 
signal elevation in the present study. This indicates the absence of scar tissue, which can result either from 
more severe acute rejection or from advanced CAV with occlusion of peripheral coronary segments. ECV 
correlated well with the amount of interstitial fibrosis in the biopsy, which is in accordance with findings in 
studies of other cardiac pathologies [17,18]. Although significant, the correlation coefficients are still 
relatively low, which might be attributed to the small sample size and the heterogeneous patient population. 
We did not observe a correlation between the IMTR and ECV, while both correlated with histological 
interstitial fibrosis. At this point it remains to be determined whether this observation relates to the number 
of study participants or the largely different spatial resolution and coverage of OCT and CMR. No local 
cohort of age-matched healthy volunteers was available to put the T1 and ECV values obtained at 3T in a 
local context; this remains of interest for follow-up studies. 
The main limitation of this pilot study is the small number of included patients, which can explain the low 
to modest areas under the curve (AUC) in the ROC analyses and the associated non-significant P-values. 
However, it should be noted that other studies in which OCT was applied for the detection of early-stage 
CAV included a similar number of study participants [6,25]. Larger patient numbers were only investigated 




In conclusion, the present pilot study tentatively confirms the hypothesis that CAV as established by 
pathologic IMTR in OCT is already associated with increase of histological interstitial fibrosis. Similar to 
other human cardiac pathology, ECV measurement and histological interstitial fibrosis correlated well in 
this study suggesting that a CMR-based ECV measurement provides an option for non-invasive detection 
of the magnitude of interstitial fibrosis in the cardiac allograft. These promising results need further 
investigation in a larger scale study, which should test both prediction of ECV for CAV and the 
reproducibility of this measure for follow-up in clinical routine. 
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Figure 1. Simplified pathogenesis of CAV with positioning of each of the examinations. Note that the 




Figure 2. Established detection of CAV through its coronary sequelae. A) An XRCA of the right 
coronary artery (RCA) of a heart transplant recipient without CAV. Note the sternal wires from the 
transplantation surgery. B) A similar XRCA in a patient with CAV degree 1. Slight atheromatosis can be 
observed as an irregular border all along the RCA, but no significant lesions are visible. C) OCT image of 
the right coronary artery in the same patient without CAV. The tunica intima and media can be seen as the 
lighter inner and darker outer vessel wall, respectively. D) In the same patient with CAV, the tunica intima 
is visibly much thicker. E-F) Segmentations of the same OCT images. Red indicates the inside of the intima, 
blue the intima-media border, and green the media-adventitia border. 
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Figure 3. Quantification of myocardial interstitial fibrosis. A) An EMB is stained blue for collagen and 
brown for muscle. B) Automated segmentation of the same slide, with a clear delineation of myocytes 
(green) and fibrosis (red). C) A midventricular native T1 map demonstrates a homogeneous myocardium 
with slightly elevated relaxation times (T1=1232±46 ms). Scale bar in ms. D) The segmented myocardium 
in colour overlaid on the rest of the map. E) Post-contrast T1 map at the same location. Note the different 
scale. F) Segmented myocardium of the post-contrast T1 map. The ECV calculated from the two T1 maps 
was 32.7±1.4%. Note that the ECV was not mapped pixel-wise, but was calculated from the averaged value 




Figure 4. Effects of cardiac allograft vasculopathy (CAV) as observed on X-ray coronary 
angiography. A-B) The intima-media ratio obtained with OCT and the percentage of fibrosis in biopsies 
show a non-significant trend towards elevation in the presence of CAV as determined by XRCA. C-D) 
Patients with CAV demonstrated a significantly higher T1 relaxation time and ECV than their counterparts 




Figure 5. Correlations of biopsy-derived interstitial fibrosis and parametric mapping. The Pearson 
correlation coefficient ρ and its significance P are indicated. A-B) EMB fibrosis correlates weakly with the 





Figure 6. Correlation between the OCT intima-media thickness ratio (IMTR) and the measurements 
of interstitial fibrosis. A) Despite assessing the tentative effects of CAV at different locations in the heart, 
IMTR and the interstitial fibrosis in the EMB correlate significantly. B-C) There is no correlation between 




Table 1. Baseline demographics of the recruited patient population.  
Age (y) 54±13 
Sex (female; % of patients) 30 
Race (Caucasian; % of patients) 100 
Time from transplant to OCT (y) 5.4±3.7 
Indication for transplant   
       Ischemic cardiomyopathy (% of patients) 30 
       Dilated non-ischemic cardiomyopathy (% of patients) 70 
Donor age (y) 38.1±15.4 
PRA>20 at transplant (% of patients)  0 
CMV mismatch (% of patients)  52 
Induction with basiliximab (% of patients)  63 
>2 treated acute cellular rejections (% of patients) 22 
Immunosuppression  
       Cyclosporine (% of patients)  41  
       Tacrolimus (% of patients)  48 
       Myocphenolate mofetil (% of patients)  81 
       Everolimus (% of patients)  22 
Diabetes (% of patients)  11 
Aspirin use (% of patients)  37 
Statin use (% of patients)  74 
Total cholesterol (mmol/L) 4.4±1.3 
LDL cholesterol (mmol/L) 2.2±1.0 
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Triglycerides (mmol/L) 2.1±1.7 
Acute cellular rejection in the index EMB (%) 0 
*OCT = optical coherence tomography, PRA = panel-reactive antibodies, CMV = cytomegalovirus, LDL = 




Table 2. Summary of the main findings with the different modalities. Continuous variables are reported 
as mean ± standard deviation in all patients, followed by the range. 
X-ray coronary angiography  
 Procedure successful  (% of all patients) 100 (27/27) 
 XRCA-CAV positive (% of procedures) 15 (4/27) 
 Non-significant focal atherosclerotic lesions (% of procedures) 41 (11/27) 
Optical coherence tomography  
 Procedure successful (% of all patients) 74 (20/27) 
 Presence of IMTR>1 (% of procedures) 75 (15/20) 
 IMTR (-) 1.56±0.63 (0.68-2.71) 
Endomyocardial biopsy   
 Procedure successful (% of all patients) 93 (25/27) 
 Degree of interstitial fibrosis (%) 29±20 (5-78) 
Cardiac magnetic resonance   
 Procedure successful (% of all patients) 100 (27/27) 
 Native T1 relaxation time (ms) 1256±49 (1169-1382) 
 ECV (%) 31.9±4.8 (26.5-49.8) 
XRCA = X-ray coronary angiography, CAV = cardiac allograft vasculopathy, IMTR = intima-media 
thickness ratio, ECV = extracellular volume 
